This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function In Patients With Central Serous Chorioretinopathy (CSC)

Stocks in this article: IRIX





MOUNTAIN VIEW, Calif., Jan. 25, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced results of a clinical study evaluating the use of IRIDEX' MicroPulse laser therapy.  The study examined the tissue-sparing therapy's effectiveness with patients diagnosed with central serous chorioretinopathy (CSC).(1) The study concluded tissue-sparing subvisible MicroPulse laser is superior to anti-VEGF injections for CSC, also known as CSR, an eye disease, which results in blurred vision typically perceived as a dark spot in the center of the field of vision. It primarily affects men between the ages of 20-50 and is often associated with type-A personalities.

"Because of the absence of laser-induced retinal damage discernable at any time postoperatively, subvisible MicroPulse photocoagulation, with no focal burn end point (or its consequences), represents an elegant medical approach and a true clinical alternative," stated co-author Prof. Frank Koch, head of the vitreo-retinal department at the University Eye Clinic of Johann Wolfgang Goethe University in Frankfurt, Germany.

"MicroPulse laser therapy is producing the kind of clinical results that we believe will fuel a paradigm shift in the treatment of retinal diseases,"  Dr. Dominik Beck President & CEO stated. "MicroPulse is a tissue-sparing therapy that we believe brings long-term therapeutic benefits with no collateral damage and can increase visual function in a very cost-effective manner. Causing no collateral damage at any time postoperatively allows for MicroPulse applications to be delivered over the entire area of CSC leakage including those near to and directly over the center of the macula (the fovea). This is a powerful vote for safety. While CSC does not impact a large population, this study is additional clinical evidence of the efficacy and safety in using MicroPulse laser therapy to treat a broader class of retinal diseases that impacts millions of Americans."

This was the first comparative, prospective evaluation of subvisible MicroPulse laser treatment and anti-VEGF injections in the treatment of CSC with regard to changes in subretinal fluid and visual function. The results indicated superior subretinal fluid resolution for MicroPulse laser compared to anti-VEGF injections, and superior improvement in visual acuity and other visual functions.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs